8/13/2019 Ranbaxy Final Pharma

1/12

Quick View Geography Sales Products Patents Deals R&D Guidance

8/13/2019 Ranbaxy Final Pharma

2/12

Ranbaxy SCREENER FINANCIALS DASHBOARD RESEARCH March -13,2013

Ranbaxy LtdIndustry: Pharmaceutical

Ranbaxy Laboratories is an India based pharmaceutical company focused on marketing generic and branded

products worldwide

Market Cap: $2 Billion Type: Mid Cap P/E: 22.5 Beta: 1.4Market Size: $500 Billion Promoters Holdings: 14%

Category: Branded Generic, API,OTC,FTF, Unbranded Generics

Top Key Markets Top Key Product Top Key Pipeline

India

US

UK

Germany

France

Pioglitazone Hydrochloride

Atorvastatin calcium

Esomeprazole magnesium

Pioglitazone - Clinical III

Pioglitazone - Clinical II

Pioglitazone - Clinical II

Ranbaxy Generics directly competes with Branded Drugs .Product Sub-Segment Annual Sales Branded DrugsPioglitazone Hydrochloride

Atorvastatin calcium

Esomeprazole magnesium

Anti-Hypertension

Anti- Diabetes

Anti- Cholesterol

Branded Drugs (Sales)

Diovan

Actos

Lipitor

$10 Billion

$20 Billion

$30 Billion

$10 Billion

$20 Billion

$30 Billion

Ranbaxy Sales Breakup

Click on any product to know more

Therapies Contribution

Anti-Infective

CVS

Pain Mgmt.

Dermatology

34%

12.7%

12.3%

8.2%

Therapies Contribution

Anti-Infective

CVS

Pain Mgmt.

Dermatology

34%

12.7%

12.3%

8.2%

Therapies Contribution

Anti-Infective

CVS

Pain Mgmt.

Dermatology

34%

12.7%

12.3%

8.2%

YOY Gr

3%

14%

3.2%

4%

YOY Gr

3%

14%

3.2%

4%

YOY Gr

3%

14%

3.2%

4%

Recent Developments1. Recall of generic Lipitor (10mg, 20mg, 40mg, 500 count bottles) from US market in November 2012, but resumed manufacturing of atorvastatin API for US market in Feb

2013. 80mg was not recalled. No recall in other markets

2. 2. Signed consent decree with USFDA with penalty of $500 mn to resume sale of drugs in US

8/13/2019 Ranbaxy Final Pharma

3/12

Ranbaxy SCREENER FINANCIALS DASHBOARD RESEARCH March -13,2013

Ranbaxy LtdIndustry: Pharmaceutical

Ranbaxy Laboratories is an India based pharmaceutical company focused on marketing generic and branded

products worldwide

Market Cap: $2 Billion Type: Mid Cap P/E: 22.5 Beta: 1.4Market Size: $500 Billion Promoters Holdings: 14%

Category: Branded Generic, API,OTC,FTF, Unbranded Generics

Top Key Markets Top Key Product Top Key Pipeline

India

US

UK

Germany

France

Pioglitazone Hydrochloride

Atorvastatin calcium

Esomeprazole magnesium

Pioglitazone - Clinical III

Pioglitazone - Clinical II

Pioglitazone - Clinical II

Ranbaxy Generics directly competes with Branded Drugs .Product Sub-Segment Annual Sales Branded DrugsPioglitazone Hydrochloride

Atorvastatin calcium

Esomeprazole magnesium

Anti-Hypertension

Anti- Diabetes

Anti- Cholesterol

Branded Drugs (Sales)

Diovan

Actos

Lipitor

Recent Developments1. Recall of generic Lipitor (10mg, 20mg, 40mg, 500 count bottles) from US market in November 2012, but resumed manufacturing of atorvastatin API for US market in Feb

2013. 80mg was not recalled. No recall in other markets

2. 2. Signed consent decree with USFDA with penalty of $500 mn to resume sale of drugs in US

Ranbaxy Sales Breakup YOY Gr

Anti-Infective

CVS

Pain Mgmt

Dermatology

YOY Gr

Anti-Infective

CVS

Pain Mgmt

Dermatology

8/13/2019 Ranbaxy Final Pharma

4/12

Ranbaxy SCREENER FINANCIALS DASHBOARD RESEARCH March -13,2013

Ranbaxy LtdIndustry: Pharmaceutical

Ranbaxy Laboratories is an India based pharmaceutical company focused on marketing generic and branded

products worldwide

Market Cap: $2 Billion Type: Mid Cap P/E: 22.5 Beta: 1.4Market Size: $500 Billion Promoters Holdings: 14%

Category: Branded Generic, API,OTC,FTF, Unbranded Generics

Top Key Markets Top Key Product Top Key Pipeline

India

US

UK

Germany

France

Pioglitazone Hydrochloride

Atorvastatin calcium

Esomeprazole magnesium

Pioglitazone - Clinical III

Pioglitazone - Clinical II

Pioglitazone - Clinical II

Ranbaxy Top Products BreakupTherapy Product Performance MAT (Cr) YoY Gr

Pain VOLINI 126 14%

Vitamins REVITAL 132 -3.2%

Anti-Infective MOX 144 -16%

CVS STORVAS 120 32%

Anti-Infective SPORIDEX 76 14%

Anti-Infective CIFRAN 32 14%

Anti-Infective MOXCLAV 88 14%

Estimated Growth

Ranbaxy Sales BreakupYOY Gr YOY Gr

Anti-Infective

CVS

Pain Mgmt

Dermatology

Anti-Infective

CVS

Pain Mgmt

Dermatology

8/13/2019 Ranbaxy Final Pharma

5/12

Quick View Market Sales Products Patents Deals R&D Guidance

Guidance

Top line of Rs. 120 bn in 2013 which includes exclusivity for Diovan

Business grew by 10%

US

India

Other Geographies

Financial Highlights

1. Recall of generic Lipitor (10mg, 20mg, 40mg, 500 count bottles) from US market in November 2012, but resumed manufacturing of atorvastatin API for US market in Feb

2013. 80mg was not recalled. No recall in other markets

2. 2. Signed consent decree with USFDA with penalty of $500 mn to resume sale of drugs in US

8/13/2019 Ranbaxy Final Pharma

6/12

Quick View Geography Sales Products Patents Deals R&D Guidance

Geography

Ranbaxy is present in 37 different location in the world, as shown on the world map Below.

Click on any Country and see quick Snapshot about the country.

8/13/2019 Ranbaxy Final Pharma

7/12

Quick View Geography Sales Products Patents Deals R&D Guidance

Sales

Ranbaxy is present in 37 different location in the world. The order below is by sales, select any

Market to see products sold.

India

US

UK

Germany

France

PAIN

VITAMIN TBK

CVS

AT

PTS

Therapy Product

8/13/2019 Ranbaxy Final Pharma

8/12

Quick View Geography Sales Products Patents Deals R&D Guidance

Sales

Ranbaxy is present in 37 different location in the world. The order below is by sales, select any

Market to see products sold.

India US UK GermanyFrance

Therapy Product

PAIN

CVS

AT

PAIN

CVS

AT

PTK

8/13/2019 Ranbaxy Final Pharma

9/12

Quick View Geography Sales Products Patents Deals R&D Guidance

Sales

Ranbaxy is present in 37 different location in the world. The order below is by sales, select any

Market to see products sold.

India US UK GermanyFrance

Therapy Product

PAIN

CVS

AT

PAIN

CVS

AT

PTK

NORMAL TABLE STRUCTRE

8/13/2019 Ranbaxy Final Pharma

10/12

Quick View Geography Sales Products Patents Deals R&D Guidance

Patents

Ranbaxy has filed 144 Patents, 25 are in Clinical Stage II, rest are in Clinical Stage III.

PAIN CVS AT PAIN CVS AT PTK PTK PTKFiled Filed

8/13/2019 Ranbaxy Final Pharma

11/12

Quick View Geography Sales Products Patents Deals R&D Guidance

Deals

8/13/2019 Ranbaxy Final Pharma

12/12

Quick View Geography Sales Products Patents Deals R&D Guidance

Recent Launch

Drug Name Launch Date NPV ($mn) Contribution

Nexium Anti-Infective 2013 135 34/Share Germany

Diovan Anti-Infective 2013 76 12/Share France

Valcyte Anti-Infective 2012 82 38/Share US

Atorvastatin Anti-Infective 2012 96 UK

Cravit Anti-Infective 2011 88 Germany

Atorva Anti-Infective 2010 77 US

CountryTherapy

Therapeutic Segment (Acute Therapy)

Therapeutic Segment (Chronic)